Othera Pharmaceuticals, a specialty pharmaceutical company, has reported positive interim data from its Phase II trial of OT-551 in treating geographic atrophy, an advanced form of dry age-related macular degeneration for which there is …
Othera Pharmaceuticals, Inc., a specialty pharmaceutical company focused on treatments for ophthalmic diseases, has announced positive interim data results from its Phase 2 trial of OT-551 in treating geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) for which there is no FDA-approved treatment.
Similarly, QLT’s innovation for macular degeneration, called Visudyne, has been very lucrative. In the case of the biotech innovations, one must consider the total product revenue to the pharmaceutical company partner, …
